Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 13;58(6):794.
doi: 10.3390/medicina58060794.

Clinical Management of Acromegaly: Therapeutic Frontiers and New Perspectives for Somatostatin Receptor Ligands (SRLs)

Alessandro Brunetti  1 , Simone Antonini  1 , Andrea Saladino  2 , Elisabetta Lavezzi  1 , Benedetta Zampetti  3 , Renato Cozzi  3
Affiliations
Review

Clinical Management of Acromegaly: Therapeutic Frontiers and New Perspectives for Somatostatin Receptor Ligands (SRLs)

Alessandro Brunetti et al. Medicina (Kaunas). .

Abstract

Somatostatin receptor ligands (SRLs) represent a true milestone in the medical therapy for acromegaly. The first-generation SRLs (FG-SRLs), octreotide and lanreotide, have demonstrated good efficacy in disease control and tumor shrinkage, and are still considered first-line medical therapies. The development of long-acting release (LAR) formulations has certainly improved the therapeutic tolerability of these drugs, although many patients still experience therapy-related burden. As such, new formulations have recently been developed to improve adherence and therapeutic efficacy and more solutions are on the way. In the case of FG-SRL-resistant disease, pasireotide, the only second generation SRL currently available, demonstrated superiority in disease control and tumor shrinkage compared to FG-SRLs. However, its use in clinical practice is still limited due to concern for impairment in glucose homeostasis. In this review, we discuss the news about the present and future role of SRLs in acromegaly, exploring the therapeutical frontiers of this drug class. Moreover, we provide practical guidance on the use of pasireotide, based on the data in the literature and our clinical experience.

Keywords: SSA; acromegaly; pituitary; somatostatin; therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Mechanism of Pasireotide-induced Hyperglycemia.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. T’Sjoen G., Bex M., Maiter D., Velkeniers B., Abs R. Health-related quality of life in acromegalic subjects: Data from AcroBel, the Belgian Registry on acromegaly. Eur. J. Endocrinol. 2007;157:411–417. doi: 10.1530/EJE-07-0356. - DOI - PubMed
    1. Holdaway I.M., Bolland M., Gamble G. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol. 2008;159:89–95. doi: 10.1530/EJE-08-0267. - DOI - PubMed
    1. Mortini P., Barzaghi L.R., Albano L., Panni P., Losa M. Microsurgical therapy of pituitary adenomas. Endocrine. 2017;59:72–81. doi: 10.1007/s12020-017-1458-3. - DOI - PubMed
    1. Buttan A., Mamelak A.N. Endocrine Outcomes After Pituitary Surgery. Neurosurg. Clin. N. Am. 2019;30:491–498. doi: 10.1016/j.nec.2019.05.009. - DOI - PubMed
    1. Giustina A., Barkhoudarian G., Beckers A., Ben-Shlomo A., Biermasz N., Biller B., Boguszewski C., Bolanowski M., Bollerslev J., Bonert V., et al. Multidisciplinary management of acromegaly: A consensus. Rev. Endocr. Metab. Disord. 2020;21:667–678. doi: 10.1007/s11154-020-09588-z. - DOI - PMC - PubMed